Fatigue News and Research

RSS

Mal-illumination - the silent epidemic

Most of human history has witnessed people living and working outdoors during the light of day, absorbing "life-charging" full-spectrum solar energy from the sky. An average of 10 hours daily in the sunlight, 70 hours weekly, was common for eons.

10 Aug 2009

Genzyme’s Mozobil approved in Europe

Genzyme Corporation announced today that the European Commission has granted marketing authorization for Mozobil ® (plerixafor injection), providing a significant new option for patients with the blood cancers lymphoma and multiple myeloma who require an autologous stem cell transplant.

6 Aug 2009

Tips to avoid heat stroke

The first sign of dangerous heat stroke can be just that – no sweat. As the temperature rises, your body’s natural cooling mechanism, sweat (or more kindly, perspiration), evaporates and helps to cool your body. But on those hot, humid cut-the-air-with-a knife days, evaporation is slowed and your body may not be able to keep itself cool.

5 Aug 2009

New understanding on Gleevec's limitations

University of Michigan researchers have developed an animal model that provides strong evidence why imatinib, marketed as Gleevec, helps patients with chronic myeloid leukemia survive longer, but does not keep the disease from returning if treatment ends.

4 Aug 2009

Dietary supplements with steroids pose health risks

Three cases of patients suffering from the adverse affects of steroid-enriched dietary supplements have been reported by researchers at Henry Ford Hospital.

4 Aug 2009

Temptation more powerful than people think

Whether it's highlighted in major news headlines about Argentinean affairs and Ponzi schemes, or in personal battles with obesity and drug addiction, individuals regularly succumb to greed, lust and self-destructive behaviors. New research from the Kellogg School of Management examines why this is the case, and demonstrates that individuals believe they have more restraint than they actually possess - ultimately leading to poor decision-making.

3 Aug 2009

FDA approves Avastin plus interferon-alfa for people with metastatic renal cell carcinoma

Genentech, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Avastin (bevacizumab) plus interferon-alfa for people with metastatic renal cell carcinoma, the most common type of kidney cancer. According to the American Cancer Society, kidney cancer is the eighth most commonly diagnosed cancer in the United States. In 2009, approximately 13,000 Americans will die from the disease.

3 Aug 2009

Major depressive disorder redefined

Researchers from Rhode Island Hospital's department of psychiatry propose that the definition for major depressive disorder (MDD) should be shortened to include only the mood and cognitive symptoms that have been part of the definition in the Diagnostic and Statistical Manual of Mental Disorders (DSM) for the past 35 years.

24 Jul 2009

Hepatitis C infection: Treatment options equally effective, likelihood of success known early on

Results of a long-awaited study of 3,070 American adults at Johns Hopkins and 118 other U.S. medical centers show that treatment with either of the two standard antiviral drug therapies is safe and offers the best way for people infected with hepatitis C to prevent liver scarring, organ failure and death.

22 Jul 2009

Sunitinib shows promise for advanced kidney cancer patients with poor prognosis

Sunitinib prolongs progression-free and overall survival, and is safe and well tolerated in advanced kidney cancer (metastatic renal cell carcinoma) patients with a poor prognosis such as the elderly and those whose cancer has spread to the brain, finds an Article published Online First (www.thelancet.com) and in the August edition of The Lancet Oncology.

16 Jul 2009

Magnetic resonance imaging accurately depicts deep endometriosis

Using magnetic resonance imaging (MRI), radiologists may be able to diagnose deep endometriosis and accurately locate lesions prior to surgery, according to a new study published in the online edition of Radiology.

7 Jul 2009

FDA approves Alimta (pemetrexed) for advanced lung cancer

The U.S. Food and Drug Administration has approved Alimta (pemetrexed), the first drug available for maintenance therapy of advanced or metastatic lung cancer.

6 Jul 2009

FDA approves Multaq tablets (dronedarone) to treat atrial fibrillation

The U.S. Food and Drug Administration has approved Multaq tablets (dronedarone) to help maintain normal heart rhythms in patients with a history of atrial fibrillation or atrial flutter (heart rhythm disorders). The drug is approved to be used in patients whose hearts have returned to normal rhythm or who will undergo drug or electric-shock treatment to restore a normal heart beat.

2 Jul 2009

HIV antibody tests unreliable for early infections in teens

A previously healthy teenager shows up at the doctor's office with a sore throat, fever, aches and general malaise. Routine blood tests are normal, an HIV test comes back negative, and the pediatrician sends the patient home with a diagnosis of acute viral infection.

21 Jun 2009

Seattle Genetics starts trial of SGN-35 for anaplastic large cell lymphoma

Seattle Genetics, Inc. (NASDAQ:SGEN), has announced that it has initiated a phase II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). SGN-35 is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics’ proprietary technology to empower antibodies by linking them to potent cell-killing drugs.

18 Jun 2009

HCV protease inhibitor telaprevir improves response, halves treatment time for hepatitis C patients

For patients with the most common form of hepatitis C, the addition of a hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy can significantly improve the chances of being cured, and it does it in half the time of standard therapy alone.

5 Jun 2009

Fatigue common after heart attack

Half of all patients who undergo myocardial infarction (heart attack) are experiencing onerous fatigue four months after the infarction. The patients who are most fatigued are those who perceive the infarction as a sign of chronic illness, those who experience the illness as difficult to control, and those who believe that the illness has a large impact on their life. These are the conclusions of a thesis presented at the Sahlgrenska Academy, University of Gothenburg, Sweden.

5 Jun 2009

Drug-resistant tuberculosis a very real threat in the Pacific region

Health officials in the Pacific are concerned about two new strains of tuberculosis - multi drug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) - both strains have been found to be resistant to the two most powerful drugs that have been used to treat tuberculosis (TB) for the past five decades.

5 Jun 2009

Bayer announces new data on novel anti-cancer compound

Bayer today announced results from Phase I and II trials of BAY 73-4506, a potent oral multi-kinase inhibitor currently being studied in multiple tumor types. These data were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).

1 Jun 2009

Marijuana effectiveness as an HIV self-care strategy

Those in the United States living with HIV/AIDS are more likely to use marijuana than those in Kenya, South Africa or Puerto Rica to alleviate their symptoms, according to a new study published in Clinical Nursing Research, published by SAGE.

31 May 2009